ramipril and Scleroderma--Diffuse

ramipril has been researched along with Scleroderma--Diffuse* in 1 studies

Other Studies

1 other study(ies) available for ramipril and Scleroderma--Diffuse

Article	Year
Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:5 Scleroderma renal crisis is the most severe renal manifestation of scleroderma and has been reported to recur rarely early after renal transplantation. Angiotensin II blockade is critical in preventing and treating scleroderma renal crisis, but some concern exists as to whether angiotensin II receptor blockers are clinically equivalent to angiotensin-converting enzyme inhibitors. The current case indicates that late recurrences of scleroderma renal crisis are possible in renal transplant recipients and that angiotensin-converting enzyme inhibitors, rather than angiotensin II receptor blockers, may be the superior drugs for such patients. Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arterioles; Basement Membrane; Female; Humans; Hypertension, Renal; Immunosuppression Therapy; Kidney Diseases; Kidney Failure, Chronic; Kidney Glomerulus; Kidney Transplantation; Losartan; Postoperative Complications; Ramipril; Recurrence; Renal Artery; Scleroderma, Diffuse	2005

Article

Year

Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:5

Scleroderma renal crisis is the most severe renal manifestation of scleroderma and has been reported to recur rarely early after renal transplantation. Angiotensin II blockade is critical in preventing and treating scleroderma renal crisis, but some concern exists as to whether angiotensin II receptor blockers are clinically equivalent to angiotensin-converting enzyme inhibitors. The current case indicates that late recurrences of scleroderma renal crisis are possible in renal transplant recipients and that angiotensin-converting enzyme inhibitors, rather than angiotensin II receptor blockers, may be the superior drugs for such patients.

Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arterioles; Basement Membrane; Female; Humans; Hypertension, Renal; Immunosuppression Therapy; Kidney Diseases; Kidney Failure, Chronic; Kidney Glomerulus; Kidney Transplantation; Losartan; Postoperative Complications; Ramipril; Recurrence; Renal Artery; Scleroderma, Diffuse

2005